These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 37328288

  • 1. Association between 6-thioguanine nucleotide levels and preventing production of antibodies to infliximab in patients with inflammatory bowel disease.
    Phillips J, Leary S, Tyrrell-Price J.
    BMJ Open Gastroenterol; 2023 Jun; 10(1):. PubMed ID: 37328288
    [Abstract] [Full Text] [Related]

  • 2. Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy.
    Yarur AJ, Kubiliun MJ, Czul F, Sussman DA, Quintero MA, Jain A, Drake KA, Hauenstein SI, Lockton S, Deshpande AR, Barkin JS, Singh S, Abreu MT.
    Clin Gastroenterol Hepatol; 2015 Jun; 13(6):1118-24.e3. PubMed ID: 25562796
    [Abstract] [Full Text] [Related]

  • 3. A Role for Thiopurine Metabolites in the Synergism Between Thiopurines and Infliximab in Inflammatory Bowel Disease.
    Mogensen DV, Brynskov J, Ainsworth MA, Nersting J, Schmiegelow K, Steenholdt C.
    J Crohns Colitis; 2018 Feb 28; 12(3):298-305. PubMed ID: 29145599
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Combination Therapy With Immunomodulators Improves the Pharmacokinetics of Infliximab But Not Vedolizumab or Ustekinumab.
    Yarur AJ, McGovern D, Abreu MT, Cheifetz A, Papamichail K, Deepak P, Bruss A, Beniwal-Patel P, Dubinsky M, Targan SR, Melmed GY.
    Clin Gastroenterol Hepatol; 2023 Oct 28; 21(11):2908-2917.e10. PubMed ID: 36280102
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
    Wong DR, Pierik M, Seinen ML, van Bodegraven AA, Gilissen LP, Bus P, Bakker JA, Masclee AA, Neef C, Engels LG, Hooymans PM.
    J Crohns Colitis; 2014 Feb 28; 8(2):120-8. PubMed ID: 23932783
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. 5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine.
    Hande S, Wilson-Rich N, Bousvaros A, Zholudev A, Maurer R, Banks P, Makrauer F, Reddy S, Burakoff R, Friedman S.
    Inflamm Bowel Dis; 2006 Apr 28; 12(4):251-7. PubMed ID: 16633046
    [Abstract] [Full Text] [Related]

  • 14. Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease.
    Bradford K, Shih DQ.
    World J Gastroenterol; 2011 Oct 07; 17(37):4166-73. PubMed ID: 22072847
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity.
    Roblin X, Peyrin-Biroulet L, Phelip JM, Nancey S, Flourie B.
    Am J Gastroenterol; 2008 Dec 07; 103(12):3115-22. PubMed ID: 19086961
    [Abstract] [Full Text] [Related]

  • 17. The potential influence of 5-aminosalicylic acid on the induction of myelotoxicity during thiopurine therapy in inflammatory bowel disease patients.
    Gao X, Zhang FB, Ding L, Liu H, Wang XD, Chen BL, Bi HC, Xiao YL, Zhao LZ, Chen MH, Huang M, Hu PJ.
    Eur J Gastroenterol Hepatol; 2012 Aug 07; 24(8):958-64. PubMed ID: 22664938
    [Abstract] [Full Text] [Related]

  • 18. Novel assay to improve therapeutic drug monitoring of thiopurines in inflammatory bowel disease.
    Vikingsson S, Andersson D, Almer S, Peterson C, Hindorf U.
    J Crohns Colitis; 2014 Dec 07; 8(12):1702-9. PubMed ID: 25239576
    [Abstract] [Full Text] [Related]

  • 19. Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease.
    Holmstrøm RB, Mogensen DV, Brynskov J, Ainsworth MA, Nersting J, Schmiegelow K, Steenholdt C.
    Dig Dis Sci; 2018 Jun 07; 63(6):1583-1591. PubMed ID: 29564674
    [Abstract] [Full Text] [Related]

  • 20. Body Mass Index and Smoking Affect Thioguanine Nucleotide Levels in Inflammatory Bowel Disease.
    Poon SS, Asher R, Jackson R, Kneebone A, Collins P, Probert C, Dibb M, Subramanian S.
    J Crohns Colitis; 2015 Aug 07; 9(8):640-6. PubMed ID: 25968584
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.